CytomX Therapeutics (CTMX) Tops Q2 EPS by 2c
Tweet
Share
E-mailGet Alerts CTMX Hot Sheet
Join SI Premium – FREE
CytomX Therapeutics (NASDAQ: CTMX) reported Q2 EPS of ($0.08), $0.02 better than the analyst estimate of ($0.10). Revenue for the quarter came in at $25.11 million versus the consensus estimate of $20 million.
For earnings history and earnings-related data on CytomX Therapeutics (CTMX) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Yalla Group Limited (YALA) Reports Q2 EPS of $0.24
- Duos Technologies Group, Inc. (DUOT) Tops Q2 EPS by 163c
- Bernstein SocGen Group Upgrades Whitbread PLC. (WTB:LN) (WTBCF) to Market Perform
Create E-mail Alert Related Categories
EarningsRelated Entities
Earnings, Maynard Um, Mark Zuckerberg, ARKSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
